A detailed history of Exome Asset Management LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Exome Asset Management LLC holds 119,467 shares of APLS stock, worth $2.87 Million. This represents 2.86% of its overall portfolio holdings.

Number of Shares
119,467
Previous 100,367 19.03%
Holding current value
$2.87 Million
Previous $2.89 Billion 31.7%
% of portfolio
2.86%
Previous 1.96%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$26.18 - $35.42 $500,038 - $676,522
19,100 Added 19.03%
119,467 $3.81 Billion
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $1.54 Million - $2.2 Million
53,467 Added 114.0%
100,367 $2.89 Billion
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $1.79 Million - $2.8 Million
46,900 New
46,900 $1.8 Billion
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $269,227 - $469,880
7,249 New
7,249 $434 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.